ABBV-706 plus atezolizumab versus standard first-line therapy for extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with previously untreated extensive-stage SCLC and ECOG 0–1 will be enrolled at multiple sites and receive either one of two IV doses of ABBV-706 with IV atezolizumab or the standard regimen of etoposide, carboplatin and atezolizumab (with optional lurbinectedin). The study includes a safety lead-in to define tolerable ABBV-706 dosing followed by an expansion phase to compare adverse events and change in disease activity across arms, targeting about 180 participants worldwide. Key eligibility requires measurable disease and brain imaging to rule out active symptomatic CNS metastases, while major exclusions include prior limited-stage therapy and active interstitial lung disease. Primary outcomes focus on safety, optimal dose selection, and change in disease activity measured by RECIST v1.1.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
* Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
* Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.

Exclusion Criteria:

* Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
* Known active/symptomatic central nervous system (CNS) metastases should be excluded.
* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan should be excluded.
* Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a life expectancy of at least 3 months.

Where it's running

• Yale University School of Medicine /ID# 278181
  New Haven, Connecticut, United States Recruiting
• University of Florida College of Medicine /ID# 277496
  Gainesville, Florida, United States Recruiting
• Ocala Oncology Center /ID# 278269
  Ocala, Florida, United States Recruiting
• Moffitt Cancer Center /ID# 277573
  Tampa, Florida, United States Recruiting
• Fort Wayne Medical Oncology And Hematology /ID# 277336
  Fort Wayne, Indiana, United States Recruiting
• Baptist Health Lexington /ID# 277729
  Lexington, Kentucky, United States Recruiting

+20 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Combining radiotherapy with immunotherapy for extensive small cell lung cancer

  This study is testing if combining radiation therapy with a type of immunotherapy can help people with extensive small cell lung cancer live longer after their initial treatment.

  Recruiting Phase 2 Regina Elena Cancer Institute · Rome, Rome · NCT06771518

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.